Top 5 Performing Stocks To Buy For 2017


One of last week’s biggest winners wasGroupon (NASDAQ:GRPN), soaring 30.2% after posting strong quarterly results.Revenue clocked in at $934.9 million for the fourth quarter, up a mere 1.9% for the top dog in daily deals.

Checking in with less than 2% in top-line growth may not seem very impressive, but it’s all relative. Groupon’s been retreating out of poorly performing overseas markets, so the quarter is actually a combination of a 5% increase in North America more than offsetting a dip in international sales. Analysts were holding out for a slight year-over-year decrease in revenue, so any degree of growth would go on to exceed expectations.


Gross billings of $1.7 billion were essentially flat with $1.71 billion a year earlier. The recently acquired LivingSocial was nearly enough to offset the slide overseas. Groupon’s net loss from continuing operations widened, but its adjusted EBITDA improved. Its adjusted net profit of $0.07 a share blew past Wall Street forecasts of $0.02 a share. It was Groupon’s first adjusted profit in two years.

Top 5 Performing Stocks To Buy For 2017: Daimler AG (DDAIF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Daimler-Mercedes (OTCPK:DDAIF)

    The Wall Street Journal reported that, “Daimler plans to unveil an electric concept car at (next month’s) Paris Auto show. Leaks suggest this will be accompanied by bullish plans to release at least six electric cars”. Of course, Daimler is already quite advanced in EVs with its partnership in China with BYD. As I write this, the Paris Auto show has begun, where “Daimler Mercedes-Benz unveiled a battery-powered sport-utility vehicle, a direct competitor to Tesla’s Model X, which will have a range of 310 miles on a single charge and is slated to launch in 2020. The vehicle will be part of a new sub-brand of Mercedes called EQ”.

  • [By John Rosevear]

    So without further ado, let’s take a closer look at the three: General Motors (NYSE:GM), Daimler AG (NASDAQOTH:DDAIF), and Delphi Automotive (NYSE:DLPH).

  • [By SEEKINGALPHA.COM]

    Last decennium, the popularity of both French Peugeot and Citro毛n has lost traction against that of German car manufacturers. PSA experienced declining sales, while German car manufacturers Volkswagen (OTCPK:VLKAY), BMW (OTCPK:BMWYY) and Daimler (OTCPK:DDAIF) have been stacking up sales records year after year over the last 6 years.

  • [By SEEKINGALPHA.COM]

    Companies like Volvo (OTCPK:VOLVY), General Motors (NYSE:GM), Suzuki (OTCPK:SZKMF), Mercedes (OTCPK:DDAIF), and Ford (NYSE:F) are all using the small Swedish company’s tech. The most prominent use for zForce is in the dashboard infotainment center, but it’s also being used as gesture control for closing the tailgate or opening a door and even in using the steering wheel.

  • [By SEEKINGALPHA.COM]

    Apart from the locals, the global competitors have also made some quick moves to make their presence felt in China. According to Reuters, Volkswagen (OTCPK:VLKAY) has recently signed a preliminary deal to set up a joint venture with China-based Anhui Jianghuai Automobile (JAC) for making electric vehicles. However, the deal has enough hurdles in its path. Also, Daimler (OTCPK:DDAIY) (OTCPK:DDAIF) is also readying some electric cars for China under the Mercedes-Benz brand.

Top 5 Performing Stocks To Buy For 2017: Eli Lilly and Company(LLY)


Advisors’ Opinion:

  • [By The Ticker Tape]

    Overall, first-quarter earnings have been pretty positive and many CEOs struck an optimistic tone discussing outlooks for the remainder of 2017. Two industrial bellwethers, General Electric Company (NYSE: GE) and Honeywell International Inc. (NYSE: HON), just beat Wall Street analyst expectations on Friday and credit card companies American Express Company (NYSE: AXP) and Visa Inc (NYSE: V) also reported strong results—some are taking that as a sign that consumer confidence could be translating into consumer buying. Next up in Q1, Eli Lilly and Co (NYSE: LLY), Lockheed Martin Corporation (NYSE: LMT), and Caterpillar Inc. (NYSE: CAT) report before market open on April 25.

  • [By Dimitra DeFotis]

    Shares of Eli Lilly (LLY) are down nearly 13% this morning after a late-stage Alzheimer’s drug trial failed to produce expected results.

    Biogen(BIIB), down nearly 6% today, also is working on an Alzheimer’s treatment; Merck (MRK) shareswere down 1% in recent trading.

    Lilly was testing the drug as a treatment for mild dementia due to Alzheimer’s disease.Credit Suisse analysts were hopeful the drug trial would show “a statistically significant impact on cognition.”MarketWatch reports:


    “Eli Lilly said it would not pursue approval for the drug to treat mild dementia due to Alzheimers disease and that it will ‘evaluate the impact of these results on the development plans for solanezumab and our other Alzheimers pipeline assets’ … More specifics about the solanezumab drug, expected the night of Dec. 9 during a meeting of the Clinical Trials on Alzheimers Disease (CTAD), could have repercussions for whats called the beta amyloid hypothesis in Alzheimers disease treatments, which target protein fragments that some believe are responsible for the disease …”


    On Nov. 15, J.P. Morgan analysts Chris Schott, Aditi Singhania, Dana Flanders and Christopher Neyor noted that trial success had a low probability. But they kept their$95 price target on the stock, noting the drug pipeline offers other opportunities. Their target implies upside of more than 40% from a recent price near $66. They wrote:

    “… On solanezumab … While the FDA recommends both cognitive and function endpoints for Alzheimers drug approvals, we expect the agency to review solanezumab on the totality of evidence, and we would not be surprised to see a cognitive benefit coupled with a trend in secondary functional endpoints be sufficient for approval … regardless of the solanezumab outcome, we see a diverse range of new product opportunities supporting LLY

  • [By Keith Speights]

    With this rapidly growing market, there are plenty of opportunities for investors. Zoetis (NYSE:ZTS), Merck (NYSE:MRK), and Eli Lilly (NYSE:LLY) stand out as the top animal-health companies to buy in 2017. Here’s why.

Top 5 Performing Stocks To Buy For 2017: Core-Mark Holding Company Inc.(CORE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Tuesday afternoon, the non-cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from GNC Holdings Inc (NYSE: GNC) and Core-Mark Holding Company, Inc. (NASDAQ: CORE).

  • [By Monica Gerson]

    Core-Mark Holding Company, Inc. (NASDAQ: CORE) is projected to report its quarterly earnings at $0.27 per share on revenue of $2.92 billion.

    Albemarle Corporation (NYSE: ALB) is estimated to post its quarterly earnings at $0.86 per share on revenue of $814.80 million.

Top 5 Performing Stocks To Buy For 2017: ThyssenKrupp AG (TYEKF)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    In addition, the company announced that it has agreed to acquire a steel plant in Brazil from ThyssenKrupp (NASDAQOTH:TYEKF) for $1.3 billion. While that plant has had its share of problems in the past, Ternium is getting it for a good value, and it has upside potential. The company paid slightly less than five times EBITDA (earnings before interest, taxes, depreciation, and amortization) for the facility. As the following chart shows, that’s below the value that steel-company stocks trade for these days:

Top 5 Performing Stocks To Buy For 2017: The Kraft Heinz Company(KHC)


Advisors’ Opinion:

  • [By Arie Goren]

    Berkshire’s largest holding, by far, in a public company is Kraft Heinz (NSDQ:KHC). It’s holding value is about $28.5 billion, about 20% of the total holding of all the 48 companies in Berkshire Hathaway’s public companies portfolio. Moreover, Berkshire owns a stake of 26.6% in the company. As such, the performance of KHC’s stock will have a significant influence on Berkshire’s future results.

  • [By WWW.THESTREET.COM]

    For his “Executive Decision” segment, Cramer sat down with Paul Polman, CEO of Unilever (UL) , home to such brands as Dove soaps and shampoos, Lipton tea, Hellmann’s mayonnaise and Vaseline, among dozens of others. On Feb. 17, Unilever rejected a hostile takeover bid from Kraft Heinz (KHC) and vowed to bring out more value as a standalone company.

  • [By Shanthi Rexaline]

    Kraft Foods, which has since then merged with Heinz to form Kraft Heinz Co (NASDAQ: KHC), had said in 2012 that SNAP made up one-sixth of its revenues.

  • [By Money Morning Staff Reports]

    Represented are Wells Fargo & Co. (NYSE: WFC), Coca-Cola Co. (NYSE: KO), and Kraft Heinz Co. (Nasdaq: KHC), just to name a few.

    The Berkshire portfolio has 34 dividend stocks in total; of those, eight yield dividend returns in excess of 3% annually, according to Buffett’s latest SEC 13F filing on Feb. 14, 2017.

  • [By Daniel Sparks]

    Shares of consumer-products company Colgate-Palmolive (NYSE:CL) increased as much as 7.4% on Wednesday on speculation thatKraft Heinz (NASDAQ:KHC)could acquire the company. Colgate stock finished the trading day up about 5.7%.

  • [By Diane Alter]

    Mondelez International stock is up this week on chatter a takeover offer from Kraft-Heinz Co. (NYSE: KHC) could be coming.

    Shares of Mondelez International Inc. (Nasdaq: MDLZ) surged 6% after hours Wednesday as rumors spread that Pittsburgh-based Kraft-Heinz might be interested in purchasing Chicago-headquartered Mondelez. German business magazine Bilanz first reported about the possible takeover.

Leave a Reply

Your email address will not be published. Required fields are marked *